ArticleCellular immunology2022
SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity.
Article in Cellular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- S309-CAR-NK cells bind the Omicron variantsJournal of virology · 2024Article
- TLR2/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells.Frontiers in immunology · 2024Article
- Article
- Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study.Journal of clinical medicine · 2023Article
- SARS-CoV-2 as an Oncolytic Virus Following Reactivation of the Immune System: A Review.International journal of molecular sciences · 2023Review
- Coordinated Loss and Acquisition of NK Cell Surface Markers Accompanied by Generalized Cytokine Dysregulation in COVID-19.International journal of molecular sciences · 2023Article
- SARS-CoV-2 infection impairs NK cell functionsFrontiers in immunology · 2023Article
- Alterations in the immune system persist after one year of convalescence in severe COVID-19 patients.Frontiers in immunology · 2023Article
- Is IFN expression by NK cells a hallmark of severe COVID-19?Cytokine · 2022Article
- Peptide-Mediated Targeted Delivery of Aloe-Emodin as Anticancer Drug.Molecules (Basel, Switzerland) · 2022Article
- Bioinformatics and System Biology Approach to Identify the Influences of COVID-19 on Rheumatoid Arthritis.Frontiers in immunology · 2022Article
- Comparison of Lung-Homing Receptor Expression and Activation Profiles on NK Cell and T Cell Subsets in COVID-19 and Influenza.Frontiers in immunology · 2022Article
- IFI44 is an immune evasion biomarker for SARS-CoV-2 andFrontiers in immunology · 2022Article
- Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.Frontiers in immunology · 2022Review
- SARS-CoV-2 induces "cytokine storm" hyperinflammatory responses in RA patients through pyroptosis.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune dysregulation is commonly observed in patients with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces severe lung inflammation and innate immune cell dysregulation. However, the precise interaction between SARS-CoV-2 and the innate immune system is currently unknown. To understand the interaction between SARS-CoV-2 and natural killer (NK) cells, several SARS-CoV-2 S protein peptides capable of binding to the NKG2D receptor were screened by in silico analysis. Among them, two peptides, cov1 and cov2, bound to NK cells and NKG2D receptors. These cov peptides increased NK cytotoxicity toward lung cancer cells, stimulated interferon gamma (IFN-γ) production by NK cells, and likely mediated these responses through the phosphorylation of Vav1, a key downstream-signaling molecule of NKG2D and NK activation genes. The direct interaction between SARS-CoV-2 and NK cells is a novel finding, and modulation of this interaction has potential clinical application as a therapeutic target for COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.